One ligand capable of <i>in situ</i> reaction in a mixed-ligand system with two new different frameworks

<p>The <i>in situ</i> ligand 2,3-pyrazinedicarboxylic acid (2,3-H₂pzdc) mixed with 1,1′-(1,4-butanediyl)bis(benzimidazole) (bbbi) is used to form two coordination polymers ([Cd(2,3-pzdc)(bbbi)] (<b>1</b>) and [Cd₂Cl₃(2-pzc)(bbbi)₂] (<b>2</b>)) under hydrothermal conditions. Complex <b>1</b> was obtained in the absence of <i>in situ</i> reaction and <b>2</b> was synthesized with 2,3-H₂pzdc <i>in situ</i> generating 2-pyrazinecarboxylate (2-pzc⁻). The structural details reveal that <b>1</b> has a 3D framework with dia topology, and <b>2</b> is a 2D layer structure and develops a 3D supramolecular structure via strong π⋯π stacking interactions. The ligand effects were compared for the two frameworks. In addition, fluorescence properties and thermal stabilities of <b>1</b> and <b>2</b> in the solid were studied.</p

Image1_Pan-cancer analyses reveal IGSF10 as an immunological and prognostic biomarker.TIF

Background: IGSF10 is a member of the immunoglobulin superfamily. Over the previous decade, growing proof has validated definitive correlations between individuals of the immunoglobulin superfamily and human diseases. However, the function of IGSF10 in pan-cancer stays unclear. We aimed to analyze the immunological and prognostic value of IGSF10 in pan-cancer.Methods: We utilized a vary of bioinformatic ways to inspect the function of IGSF10 in pan-cancer, including its correlation with prognosis, immune cell infiltration, tumor mutational burden (TMB), microsatellite instability (MSI), mismatch repair (MMR), DNA methyltransferases, genetic alteration, drug sensitivity, etc.Results: We noticed low expression of IGSF10 in most cancer types. IGSF10 expression in tumor samples correlates with prognosis in most cancers. In most cancer types, IGSF10 expression was strongly related to immune cells infiltration, immune checkpoints, immune modulators, TMB, MSI, MMR, and DNA methyltransferases, among others. Functional enrichment analyses indicated that IGSF10 expression was involved in lymphocyte differentiation, cell molecules adhesion, etc. Furthermore, low IGSF10 expression could increase the drug sensitivity of many drugs.Conclusion:IGSF10 could serve as a novel prognostic marker and attainable immunotherapy target for several malignancies.</p

The fluorescence images of nucleus-located β-catenin in NANOGP8-transfected and mock cells.

<p><b>A.</b> Accumulated β-catenin in nucleus of the NANOGP8-transfected cells (SGC7901-NANOGP8); <b>B.</b> Very weak or undetectable β-catenin in nucleus of the mock-cells (SGC7901-MOCK) without NANOGP8 transfection.</p

Primers used in this study.

<p>Primers used in this study.</p

NANOGP8 over-expression enhances EMT and CSC Markers.

<p><b>A.</b> Comparison of EMT genes in NANOGP8-transfected SGC7901 cells (SGC7901-NANOGP8) and mock-transfected SGC7901 cells (SGC7901-NC). **<i>p</i><0.01. <b>B.</b> Expression of CSC marker genes in NANOGP8-transfected SGC7901 cells and mock-transfected SGC7901 cells. **<i>p</i><0.01. <b>C.</b> Expression of ABCG2 and MSI1 genes in NANOGP8-transfected SGC7901 cells and mock-transfected SGC7901 cells. **p<0.01. <b>D.</b> Protein detection of EMT and CSC markers in NANOGP8-transfected SGC7901 cells (NANOGP8) and mock-transfected SGC7901 cells (NC). <b>D1.</b>Comparison of N-cad protein expression in NANOGP8-transfected SGC7901 cells (NANOGP8) and mock-transfected SGC7901 cells (NC); <b>D2.</b> Comparison of NANOGP8 protein expression in NANOGP8-transfected SGC7901 cells (NANOGP8) and mock-transfected SGC7901 cells (NC); <b>D3.</b> Comparison of Lgr5 protein expression in NANOGP8-transfected SGC7901 cells (NANOGP8) and mock-transfected SGC7901 cells (NC); <b>D4.</b> Comparison of vimentin protein expression in NANOGP8-transfected SGC7901 cells (NANOGP8) and mock-transfected SGC7901 cells (NC); <b>D5.</b> Comparison of CD44 protein expression in NANOGP8-transfected SGC7901 cells (NANOGP8) and mock-transfected SGC7901 cells (NC); <b>D6.</b> Comparison of E-cad protein expression in NANOGP8-transfected SGC7901 cells (NANOGP8) and mock-transfected SGC7901 cells (NC).</p

Detection of <i>NANOG-1</i> and <i>NANOGP8</i> expression by qPCR.

<p><b>A.</b> Diagram of the gene structures of NANOG-1 and NANOGP8, note that the most 5’ of the first exon in NANOG1 gene contains a stretch of 21nt unique sequences; <b>B.</b> Diagram of the sequence locations of the primers designed to distinguish PCR products amplified from NANOG1 and NANOGP8. NANOG1/P8 stands for common primers shared by NANOG1 and NANOGP8 that can amplify DNA from both NANOG1 and NANOGP8 cDNA, and NANOG1-s stands for NANOG1-specific primers that only can amplify DNA from NANOG1 cDNA; <b>C.</b> Expression of NANOG1 and NANOG1/NANOGP8 in sphere-forming cells versus parental adherent cells derived from different cell lines. **<i>p</i><0.01.</p

Flow cytometry analysis of cell cycle in NANOGP8-transfected, mock-transfected, and SGC7901 cells.

<p><b>A.</b> Cell cycle in NANOGP8-transfected SGC7901 cells; <b>B.</b> Cell cycle in mock-transfected cells; <b>C.</b> Cell cycle in SGC7901 cells.</p

Fabrication and Catalytic Performance of Highly Stable Multifunctional Core–Shell Zeolite Composites

Multifunctional Fe₃O₄@SiO₂–Au@silicalite-1 core–shell magnetic zeolite composites were fabricated by combining a series of sol–gel process and vapor-phase transfer of silicalite-1 zeolite nanocrystal-seeded silica shells. The obtained composite has high magnetization (32.00 emu/g), stably confined and active gold nanoparticles (ca. 15 nm), and a hierarchical silicalite-1 outer shell. The core–shell composite exhibits a high efficiency of magnetic separability, excellent catalytic performance, and reusability for the reduction of 4-nitrophenol with conversion of 98% in 12 min. Moreover, it preserves a good stability after a high-temperature hydrothermal treatment

The impact of NANOGP8 on cell cycle in NANOGP8-transfected, mock and SGC7901 cells.

<p><b>(%, mean ±</b> SD).</p

Immunofluorescence staining of LGR5 and NANOGP8 in SGC7901 cells and spheres.

<p><b>A.</b> SGC7901 adherent cells; <b>B.</b> SGC7901 sphere-forming cells; <b>C.</b> NANOGP8-transfected SGC7901 adherent cells; <b>D.</b> NANOGP8-transfected SGC7901 sphere-forming cells. Note the localization and expression of NANOGP8 and Lgr5 were visualized. All the images are 200× magnified.</p